1-2 of 2
Mark Hoffman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective cohort studies

Free
Catherine Thieblemont, Emmanuelle Tchernonog, Talha Munir, Oliver Miles, Ingo Schwaner, Ugo Consoli, Vanessa Innao, Anna Mele, Danielle De Farias, Adriana Scheliga, Neil Kay, Ahmed Absi, Galia Stemer, Tamar Tadmor, Mark Hoffman, Brian Koffman, Boo Messahel, Sowmya Srikanthan, Erin Franceschini, Christopher Abbazio, Ping Xu, Christoph Tapprich, Claire Kavanagh, Mohamed Fouad, Lori Parisi, Mark Wildgust, Paolo Ghia
Journal: Blood
Blood (2025) 146 (Supplement 1): 3903.
https://doi.org/10.1182/blood-2025-3903
Published: 2025
Journal Articles

A Combination of Rituxan, Cyclophosphamide and Dexamethasone (RCD) Results in Long-Lasting Responses in Autoimmune Anemia and Thrombocytopenia in CLL Patients: A Single Institution Study.

Free
Matthew S. Kaufman, MD, Yehuda Z. Lebowicz, MD, Nancy Driscoll, RPA-C, Christina Johnson, RPA-C, Dale Janson, RPA-C, Angelica Caramanica, RPA-C, Rajasree Roy, MD, Neetu Radhakrishnan, MD, Dhaval Mehta, MD, Mark Hoffman, MD, Dilip Patel, MD, Nina Kohn, MBA,MA, Kanti R. Rai, MD
Journal: Blood
Blood (2006) 108 (11): 2832.
https://doi.org/10.1182/blood.V108.11.2832.2832
Published: 2006